EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007)

Chenguang Wang, Chaoxin Zhou, Sheng Hou, Wenqiang Fan, Weizhu Qian, Yule Ren, Xiyuan Chen, Chenhong Pan iD, Qingcheng Guo, Huaizu Guo iD, Yajun Guo

Pharmaceuticals · 02.05.2026 · 19 (5) · 724

DOI: 10.3390/ph19050724 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 02.05.2026. Verfasst von Chenguang Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 3250…. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Leading Talent Program of Eastern Talent Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Post-approval manufacturing changes for biologics require rigorous comparability assessments to ensure uninterrupted quality and clinical performance. CMAB007 (Aomaishu®), a China-approved (2023) omalizumab biosimilar, underwent process enhancements—including media optimization and anion-exchange chromatography substitution—yielding a 5-fold increase in production without altering the host cell line.

Methods

A novel three-arm tiered strategy was adopted to compare post-change CMAB007, pre-change CMAB007, and reference (Xolair®) products. Critical quality attributes (CQAs) were classified into tiers based on risk impact, with tier-specific acceptance criteria. Comprehensive analytics assessed structure, post-translational modifications, purity/impurities, activity, and Fc-mediated functions. Forced degradation (lyophilized/reconstituted states) and accelerated stability studies were evaluated. Based on the high degree of CMC similarity and to prevent “biological drift”, the pharmacokinetic (PK) and safety comparability of the post-change CMAB007 versus the reference product (Xolair®) was confirmed in a randomized, double-blind, two-arm study in healthy males (N = 114; single 150 mg subcutaneous administration). The pre-change product was not included in this clinical PK study.

Results

Post-change CMAB007 exhibited analytical similarity within tiered acceptance criteria for all CQAs. Stability studies confirmed enhanced robustness under stress conditions. PK equivalence was demonstrated for AUC0–inf (GMR: 99.82%; 90% CI: 91.46~108.94%), AUC0–t (99.54%; 91.40~108.41%), and Cmax (101.88%; 95.21~109.01%). Immunogenicity (ADA incidence: 10.5% vs. 12.5%, p = 0.742) and safety profiles were comparable.

Conclusions

This study pioneers a tiered three-arm comparability strategy for post-approval changes, integrating advanced analytics, risk-based quality assessment, and clinical validation. The approach mitigates “biological drift” risks, ensuring biosimilar quality, efficacy, and safety while enabling sustainable production scalability.

Schlagwörter

Stichwörter der Autor:innen

CMAB007omalizumab biosimilarpost-approval changesthree-arm comparability strategy

Autor:innen und Institutionen

  • State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
  • State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, NMPA Key Laboratory for Quality Control of Therapeutic Monoclonal Antibodies, Shanghai Zhangjiang Biotechnology Co., Ltd., Shanghai 201203, China.
  • State Key Laboratory of Macromolecular Drugs and Large-Scale Preparation, School of Pharmaceutical Sciences and Food Engineering, Liaocheng University, Liaocheng 252000, China.
  • Taizhou Mabtech Pharmaceuticals Co., Ltd., Taizhou 225300, China.

ORCID-Profile: Chenhong Pan, Huaizu Guo

Förderung

  • Shanghai Leading Talent Program of Eastern Talent Plan

Zitieren

APA

Wang, C., Zhou, C., Hou, S., Fan, W., Qian, W., Ren, Y., Chen, X., Pan, C., Guo, Q., Guo, H., & Guo, Y. (2026). A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007). Pharmaceuticals, 19(5), 724. https://doi.org/10.3390/ph19050724

Vancouver

Wang C, Zhou C, Hou S, Fan W, Qian W, Ren Y, et al. A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007). Pharmaceuticals. 2026;19(5):724. doi:10.3390/ph19050724

BibTeX
@article{Wang2026,
  author = {Wang, Chenguang and Zhou, Chaoxin and Hou, Sheng and Fan, Wenqiang and Qian, Weizhu and Ren, Yule and Chen, Xiyuan and Pan, Chenhong and Guo, Qingcheng and Guo, Huaizu and Guo, Yajun},
  title = {A Three-Arm, Tiered Comparability Strategy Bridging Post-Approval Process Changes for an Omalizumab Biosimilar (CMAB007)},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {5},
  pages = {724},
  doi = {10.3390/ph19050724}
}
Kostenlos starten →